Live·Open questions in longevity research
All news
Biotech fundingAI in medicineLongevity research

$50 million in grants for biological data for AI will do more for human health than $5 billion for drug developer Isomorphic Labs, says the founder of Impetus Grants

21 November 2026· 261121004

$50 million in grants for biological data for AI will do more for human health than $5 billion for drug developer Isomorphic Labs, says the founder of Impetus Grants

On November 18, biologist Martin Jensen (Martin Borch Jensen) proposed funding publicly available biological data. He is seeking philanthropic donors for the next round of his aging research program, Impetus Grants: $15 million for approximately 50 projects.

In October, Jensen compared $50 million for studies following people over several years with a leading AI lab’s daily spending on computing. He now compares the benefits of these grants with those of a specific funding round: Isomorphic Labs announced that it had raised $5 billion the previous day, November 17. The company plans to develop models for designing drug molecules, study disease biology, and prepare drugs for human trials. Jensen proposes funding data that researchers across institutions can use to train models and test their predictions about treatment.

Jensen’s proposal calls for researchers to relate changes in blood or tissue composition to organ function and subsequent health in the same patient. He explains that the same cellular state can affect the body differently depending on the surrounding tissue. For example, researchers could relate blood composition to changes in a patient’s memory after treatment for Alzheimer’s disease. A model would use these data to learn to predict disease progression and treatment response. Its predictions could then be compared with findings from subsequent follow-up. In his appeal to donors, Jensen writes:

“Some of these observations will take years, however quickly intelligence improves.”

Impetus plans to launch new studies and use stored blood and tissue samples from earlier studies that have already tracked participants’ health after sample collection. Researchers will measure levels of proteins, lipids, and metabolites in the stored samples and relate the results to participants’ recorded health histories. The program expects this approach to provide data spanning several years sooner: the years of follow-up have already elapsed, and more detailed molecular measurements will now be added. In parallel, new studies will track disease progression and treatment response.

Jensen founded Impetus after being inspired by Fast Grants, a program that rapidly awarded funding for COVID-19 research. He brought this approach to aging research, where faster selection allows studies requiring years of follow-up to begin sooner. The current round will use short initial applications; selected teams will submit detailed plans. A biologist and a machine learning specialist will assess the scientific rationale and whether the resulting data will be suitable for training and testing models.

Donors have pledged $9,1 million for the round toward the $15 million needed; another $5,9 million must be raised before applications open. The program requires teams to publish datasets with descriptions of the measurements so that other researchers can use them; access to human data may be restricted to protect personal information. Norn Group, the nonprofit organization that runs Impetus, describes its goal as follows:

“We build data centers to meet anticipated demand for computing. The same logic applies to data.”

Originally published on Telegram by Ukhvat NewsView on Telegram
Sources
#impetus-grants#biological-data#longitudinal-studies#machine-learning#aging-research#isomorphic-labs